Protein Kinase C recognition sites in the cytoplasmic domain of Endothelin Converting Enzyme-1c

Biochemical and Biophysical Research Communications

Volumn 427, Issue 3, 2012, Pages 606-610

  Kuruppu, Sanjaya ^a   Tochon Danguy, Nathalie ^a,b   Smith, A Ian ^a  

^a MONASH UNIVERSITY   (Australia)

^b Victoria College of Pharmacy ^*  (Australia)

Author keywords

Endothelin Converting Enzyme 1; Endothelin 1; Enzyme trafficking; Phosphorylation; Protein Kinase C; Vasoconstrictor

Indexed keywords

ENDOTHELIN 1; ENDOTHELIN CONVERTING ENZYME; ENDOTHELIN CONVERTING ENZYME 1C; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BINDING SITE; CATALYSIS; CONTROLLED STUDY; CYTOPLASM; ENZYME ACTIVATION; FEMALE; MUTANT; MUTATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PROTEIN TRANSPORT; WILD TYPE;

ANIMALS; ASPARTIC ACID ENDOPEPTIDASES; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CYTOPLASM; GENE KNOCKOUT TECHNIQUES; HEK293 CELLS; HUMANS; METALLOENDOPEPTIDASES; MICE; MUTATION; PHOSPHORYLATION; PROTEIN KINASE C; PROTEIN STRUCTURE, TERTIARY; TETRADECANOYLPHORBOL ACETATE;

EID: 84867867194     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.09.105     Document Type: Article

References (29)

1. Sakurai T., Goto K. Endothelins. vascular actions and clinical implications. Drugs 1993, 46:795-804.
2. Ohnaka K., Takayanagi R., Nishikawa M., Haji M., Nawata H. Purification and characterization of a phosphoramidon-sensitive endothelin-converting enzyme in porcine aortic endothelium. J. Biol. Chem. 1993, 268:26759-26766.
3. Smollich M., Wulfing P. Targeting the endothelin system: novel therapeutic options in gynecological, urological and breast cancers. Expert. Rev. Anticancer Ther. 2008, 8:1481-1493.
4. Jeng A.Y. Utility of endothelin-converting enzyme inhibitors for the treatment of cardiovascular diseases. Curr. Opin. Investig. Drugs 2003, 4:1076-1081.
5. Martinez-Miguel P., Raoch V., Zaragoza C., Valdivielso J.M., Rodriguez-Puyol M., Rodriguez-Puyol D., Lopez-Ongil S. Endothelin-converting enzyme-1 increases in atherosclerotic mice: Potential role of oxidized low density lipoproteins. J. Lipid Res. 2009, 50:364-375.
6. Pluta R.M., Boock R.J., Afshar J.K., Clouse K., Bacic M., Ehrenreich H., Oldfield E.H. Source and cause of endothelin-1 release into cerebrospinal fluid after subarachnoid hemorrhage. J. Neurosurg. 1997, 87:287-293.
7. Choi D.S., Wang D., Yu G.Q., Zhu G., Kharazia V.N., Paredes J.P., Chang W.S., Deitchman J.K., Mucke L., Messing R.O. PKC epsilon increases endothelin converting enzyme activity and reduces amyloid plaque pathology in transgenic mice. Proc. Nat. Acad. Sci. USA 2006, 103:8215-8220.
8. Funalot B., Ouimet T., Claperon A., Fallet C., Delacourte A., Epelbaum J., Subkowski T., Leonard N., Codron V., David J.P., Amouyel P., Schwartz J.C., Helbecque N. Endothelin-converting enzyme-1 is expressed in human cerebral cortex and protects against Alzheimer's disease. Mol. Psychiatry 2004, 9:1122-1128.
9. Higuchi M., Iwata N., Saido T.C. Understanding molecular mechanisms of proteolysis in Alzheimer's disease: progress toward therapeutic interventions. Biochim. Biophys. Acta 2005, 1751:60-67.
10. Schweizer A., Valdenaire O., Nelbock P., Deuschle U., Dumas Milne Edwards J.B., Stumpf J.G., Loffler B.M. Human endothelin-converting enzyme (ECE-1): three isoforms with distinct subcellular localizations. Biochem. J. 1997, 328(Pt. 3):871-877.
11. Valdenaire O., Lepailleur-Enouf D., Egidy G., Thouard A., Barret A., Vranckx R., Tougard C., Michel J.B. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter molecular cloning and characterization. Eur. J. Biochem. 1999, 264:341-349.
12. Jafri F., Ergul A. Phosphorylation of endothelin converting enzyme-1 isoforms: relevance to subcellular localization. Exp. Biol. Med. (Maywood) 2006, 231:713-717.
13. Fahnoe D.C., Knapp J., Johnson G.D., Ahn K. Inhibitor potencies and substrate preference for endothelin-converting enzyme-1 are dramatically affected by pH. J. Cardiovasc. Pharmacol. 2000, 36:S22-S25.
14. Kuruppu S., Smith A.I. Endothelin converting enzyme-1 phosphorylation and trafficking. FEBS Lett. 2012, 586:2212-2217.
15. Nelboeck P., Fuchs M., Bur D., Loffler B.M. Glycosylation of Asn-632 and Asn-651 is important for functional expression of endothelin-converting enzyme-1. J. Cardiovasc. Pharmacol. 1998, 31(Suppl. 1):S4-S6.
16. Schweizer A., Loffler B.M., Rohrer J. Palmitoylation of the three isoforms of human endothelin-converting enzyme-1. Biochem. J. 1999, 340(Pt 3):649-656.
17. MacLeod K.J., Husain R.D., Gage D.A., Ahn K. Constitutive phosphorylation of human endothelin-converting enzyme-1 isoforms. J. Biol. Chem. 2002, 277:46355-46363.
18. Kuruppu S., Tochon-Danguy N., Ian Smith A. Role of protein kinase C in endothelin converting enzyme-1 trafficking and shedding from endothelial cells. Biochem. Biophys. Res. Commun. 2010, 398:173-177.
19. Smith A.I., Lew R.A., Thomas W.G., Tochon-Danguy N. Protein kinase C regulates the cell surface activity of endothelin-converting enzyme-1. Int. J. Pept. Res. Ther. 2006, 12:291-295.
20. Keynan S., Khamaisi M., Dahan R., Barnes K., Jackson C.D., Turner A.J., Raz I. Increased expression of endothelin-converting enzyme-1c isoform in response to high glucose levels in endothelial cells. J. Vasc. Res. 2004, 41:131-140.
21. Khamaisi M., Dahan R., Hamed S., Abassi Z., Heyman S.N., Raz I. Role of protein kinase C in the expression of endothelin converting enzyme-1. Endocrinology 2009, 150:1440-1449.
22. Kuruppu S., Reeve S., Ian Smith A. Characterisation of endothelin converting enzyme-1 shedding from endothelial cells. FEBS Lett. 2007, 581:4501-4506.
23. Ahn K., Pan S., Beningo K., Hupe D. A permanent human cell line (EA.hy926) preserves the characteristics of endothelin converting enzyme from primary human umbilical vein endothelial cells. Life Sci. 1995, 56:2331-2341.
24. Anstadt M.P., Hutchinson J., Portik-Dobos V., Jafri F., Bannan M., Mawulawde K., Ergul A. Vascular endothelin converting enzyme-1 expression and activity is upregulated in clinical diabetes. Ethn. Dis. 2002, 12. pp. S3-5-S3-9.
25. Jafri F., Ergul A. Nuclear localization of endothelin-converting enzyme-1: subisoform specificity. Arterioscler. Thromb. Vasc. Biol. 2003, 23:2192-2196.
26. Blaukat A., Pizard A., Breit A., Wernstedt C., Alhenc-Gelas F., Muller-Esterl W., Dikic I. Determination of bradykinin B2 receptor in vivo phosphorylation sites and their role in receptor function. J. Biol. Chem. 2001, 276:40431-40440.
27. Soskic V., Nyakatura E., Roos M., Muller-Esterl W., Godovac-Zimmermann J. Correlations in palmitoylation and multiple phosphorylation of rat bradykinin B2 receptor in chinese hamster ovary cells. J. Biol. Chem. 1999, 274:8539-8545.
28. Prowse C.N., Lew J. Mechanism of activation of ERK2 by dual phosphorylation. J. Biol. Chem. 2001, 276:99-103.
29. Ganju R.K., Shpektor R.G., Brenner D.G., Shipp M.A. CD10/neutral endopeptidase 24.11 is phosphorylated by casein kinase II and coassociates with other phosphoproteins including the lyn src-related kinase. Blood 1996, 88:4159-4165.